Ensysce Biosciences, Inc. (ENSC)
0.4803
+0.01
(+1.54%)
USD |
NASDAQ |
Sep 09, 10:55
Ensysce Biosciences Total Liabilities (Quarterly) : 4.068M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.068M |
| March 31, 2026 | 2.837M |
| December 31, 2025 | 4.568M |
| September 30, 2025 | 2.305M |
| June 30, 2025 | 2.514M |
| March 31, 2025 | 1.891M |
| December 31, 2024 | 2.217M |
| September 30, 2024 | 2.805M |
| June 30, 2024 | 1.316M |
| March 31, 2024 | 1.654M |
| December 31, 2023 | 3.359M |
| September 30, 2023 | 2.061M |
| June 30, 2023 | 2.565M |
| March 31, 2023 | 4.067M |
| December 31, 2022 | 9.915M |
| September 30, 2022 | 14.71M |
| June 30, 2022 | 8.747M |
| March 31, 2022 | 11.26M |
| Date | Value |
|---|---|
| December 31, 2021 | 24.58M |
| September 30, 2021 | 10.10M |
| June 30, 2021 | 4.029M |
| March 31, 2021 | 11.09M |
| December 31, 2020 | 7.010M |
| September 30, 2020 | 8.018M |
| June 30, 2020 | 8.360M |
| March 31, 2020 | 52.06M |
| December 31, 2019 | 10.34M |
| September 30, 2019 | 8.134M |
| June 30, 2019 | 7.340M |
| March 31, 2019 | 7.387M |
| December 31, 2018 | 7.440M |
| September 30, 2018 | 7.359M |
| June 30, 2018 | 7.135M |
| March 31, 2018 | 7.197M |
| December 31, 2017 | 7.156M |
| September 30, 2017 | 0.38M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.641M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.957M |
| Shareholders Equity (Quarterly) | -0.7817M |
| Debt to Equity Ratio | -0.2518 |
| Current Ratio | 0.6031 |
| Net Debt Paydown Yield | 0.18% |